Easy Check
Acetone is present in the expiration of any human. It is known from clinical practice and medical research that the presence of particular levels of acetone in the exhaled air most often points to diabetes mellitus. Moreover, clinical laboratory studies show that there is a quantitative correlation between glucose content in blood and acetone concentration in the exhaled air. Although the association between acetone levels in the breath and glucose is well documented, previous data on the acetone/glucose correlation has been insufficient for reliable statistics.
The Easy Check breath glucose test, currently under development, is a non-invasive glucose detection system that measures the levels of acetone in a patient’s exhaled breath. The Easy Check breath glucose detection system combines a proprietary chemical mixture with exhaled breath, which creates a new molecular compound that can be measured with the Company’s patent-pending technology. The Company believes that its technology generates a chemical reaction that can be reliably measured and accurately depicts a patient’s blood glucose level. This could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading.
Continued research and development efforts of the Company’s scientific team, based in Israel, have led to the initial design completion of the Easy Check chemical sensor, a single-use capsule that contains a proprietary chemical reagent, which mixes with the volatile organic chemicals in a patient’s exhaled breath to create a chemical reaction that is measured by the device’s optical density sensors. The readings are immediately translated by the device's software into blood glucose measurements that are expected to correlate closely to glucose readings obtained by conventional blood glucose measuring devices.
PositiveID plans to conduct laboratory-based comparisons of the non-invasive Easy Check breath glucose analysis system versus the current standard “finger stick” blood glucose testing method. The Company plans to launch the laboratory analysis in Bet Shemesh, Israel, and believes the results from this lab-based study may facilitate the development of the prototype handheld Easy Check breath-based device.
 |
|
